Cabazitaxel in prostate cancer: stretching a string.
Dorff
Tanya B
TB
University of Southern California, Division of Oncology, Kenneth J Norris Comprehensive Cancer Center, Los Angeles, CA 90033, USA.
Quinn
David I
DI
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000494:pharmacology; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D017277:Drug Approval; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008942:Mitoxantrone / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011788:Quality of Life; D043823:Taxoids / Q000008:administration & dosage / Q000627:therapeutic use*; D014020:Tissue Extracts / Q000008:administration & dosage / Q000494:pharmacology
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D019496:Cancer Vaccines; D043823:Taxoids; D014020:Tissue Extracts; D000077143:Docetaxel; D004961:Estramustine; C552428:cabazitaxel; C511774:sipuleucel-T; D008942:Mitoxantrone; D011241:Prednisone